E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

10.1158/1538-7445.sabcs14-ot2-1-06 ◽

2015 ◽

Cited By ~ 5

Author(s):

Roisin M Connolly ◽

Fengmin Zhao ◽

Kathy D Miller ◽

Amye J Tevaarwerk ◽

Lynne I Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.501 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 501-501 ◽

Cited By ~ 11

Author(s):

Maura N. Dickler ◽

William Thomas Barry ◽

Constance T. Cirrincione ◽

Matthew James Ellis ◽

Mary Ellen Moynahan ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

10.1158/1538-7445.sabcs15-ot2-01-04 ◽

2016 ◽

Author(s):

R Connolly ◽

F Zhao ◽

K Miller ◽

A Tevaarwerk ◽

L Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Research Group ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy424.011 ◽

2018 ◽

Vol 29 ◽

pp. viii709 ◽

Cited By ~ 1

Author(s):

Z. Jiang ◽

W. Li ◽

X. Hu ◽

Q. Zhang ◽

T. Sun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Histone Deacetylase ◽

Hdac Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Subtype Selective

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy155 ◽

2018 ◽

Vol 29 (7) ◽

pp. 1541-1547 ◽

Cited By ~ 148

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz215 ◽

2019 ◽

Vol 30 (11) ◽

pp. 1842 ◽

Cited By ~ 6

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Abstract P6-18-07: Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials

10.1158/1538-7445.sabcs18-p6-18-07 ◽

2019 ◽

Cited By ~ 3

Author(s):

DA Yardley ◽

A Chan ◽

A Nusch ◽

GS Sonke ◽

Y-S Yap ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Visceral Metastases

283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.385 ◽

2020 ◽

Vol 31 ◽

pp. S354-S355

Author(s):

N. Turner ◽

R. Dent ◽

J. O'Shaughnessy ◽

S-B. Kim ◽

S. Isakoff ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Abstract PD2-08: Ribociclib with endocrine therapy for premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7 trial

10.1158/1538-7445.sabcs18-pd2-08 ◽

2019 ◽

Cited By ~ 1

Author(s):

A Bardia ◽

M Colleoni ◽

S Campos-Gomez ◽

KH Jung ◽

P Wheatley-Price ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Cancer Biomarker ◽

Advanced Breast ◽

Phase Iii ◽

Premenopausal Patients

Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3719091 ◽

2020 ◽

Author(s):

Howard Burris ◽

Arlene Chan ◽

Aditya Bardia ◽

J. Thaddeus Beck ◽

Joohyuk Sohn ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Pooled Analysis ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trials ◽

Dose Reductions